<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687631</url>
  </required_header>
  <id_info>
    <org_study_id>TRUST</org_study_id>
    <nct_id>NCT04687631</nct_id>
  </id_info>
  <brief_title>Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases</brief_title>
  <official_title>Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases: mFOLFOXIRI Plus Cetuximab Versus mFOLFOXIRI Plus Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evidence suggests that the addition of cetuximab or bevacizumab to doublet regimens could&#xD;
      improve response rate and resectability rate of liver metastases and survival in colorectal&#xD;
      liver metastases (CRLM). Moreover, it is observed that FOLFOXIRI yields higher response and&#xD;
      resection rates compared with doublet regimens. However, which is better in conversion&#xD;
      therapy of RAS/BRAF wild-type initially unresectable CRLM, FOLFOXIRI plus cetuximab or&#xD;
      bevacizumab, remains unknown.&#xD;
&#xD;
      In this study, RAS/BRAF wild-type colorectal cancer patients with initially unresectable&#xD;
      liver-only metastases, as prospectively confirmed by a local multidisciplinary team (MDT)&#xD;
      according to predefined criteria, will be randomised between modified FOLFOXIRI (mFOLFOXIRI)&#xD;
      plus cetuximab and mFOLFOXIRI plus bevacizumab. Patient imaging will be reviewed for&#xD;
      resectability by MDT, consisting of at least one radiologist and three liver surgeons every&#xD;
      assessment. MDT review will be performed prior to randomization as well as during treatment,&#xD;
      as described in the protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be stratified for primary tumor location (right-sided or left sided) and&#xD;
      numbers of liver metastases (&lt;5 or ≥5).&#xD;
&#xD;
      Patients with RAS mutated primary tumors will be randomized between mFOLFOXIRI plus cetuximab&#xD;
      (cetuximab 500 mg/m^2 in 60 minutes i.v., followed by oxaliplatin 85 mg/m^2 i.v. in 120&#xD;
      minutes, followed by irinotecan 165 mg/m^2 i.v. in 60 minutes, together with leucovorin 400&#xD;
      mg/m^2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 2400 mg/m^2 in&#xD;
      46 hours, every 2 weeks) or mFOLFOXIRI plus bevacizumab (Bevacizumab 5 mg/kg in 15-30 minutes&#xD;
      i.v., followed by oxaliplatin 85 mg/m^2 i.v. in 120 minutes, followed by irinotecan 165&#xD;
      mg/m^2 i.v. in 60 minutes, together with leucovorin 400 mg/m^2 i.v. in 120 minutes, followed&#xD;
      by continuous infusion of 5-fluorouracil 2400 mg/m^2 in 46 hours, every 2 weeks).&#xD;
&#xD;
      Patients will be evaluated every 8 weeks by MRI or CT scan for disease status. The assigned&#xD;
      systemic treatment should be continued for at least 6 months or earlier in case of&#xD;
      resectability, progression of disease, unacceptable toxicity, or patient refusal. If after 6&#xD;
      months MDT concludes that the patient is still not resectable, it is highly unlikely that&#xD;
      resectability will be achieved at all. Therefore the chemotherapy regimen may be reconsidered&#xD;
      after 6 months of treatment.&#xD;
&#xD;
      In patients who will become resectable and undergo secondary surgery of liver metastases, the&#xD;
      total duration of preoperative and postoperative treatment together should be 6 months.&#xD;
      However, the postoperative chemotherapy regimen was determined by the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conversion resection rate of liver metastases</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Rate of conversion from initially unresectable liver metastases to resectable ones</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 6 months</time_frame>
    <description>rate of objective response for therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Incidence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early tumor shrinkage</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>The rates of tumor shrinkage by RECIST at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best deepness of response</measure>
    <time_frame>up to 6 months</time_frame>
    <description>the maximum tumor shrinkage rates by RECIST during the treatment of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">474</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>mFOLFOXIRI plus Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFOXIRI plus Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOXIRI plus Cetuximab</intervention_name>
    <description>cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks</description>
    <arm_group_label>mFOLFOXIRI plus Cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOXIRI Plus Bevacizumab</intervention_name>
    <description>bevacizumab 5mg/kg + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks</description>
    <arm_group_label>mFOLFOXIRI plus Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The primary tumor was confirmed by histology as colorectal adenocarcinoma&#xD;
&#xD;
          2. Initially unresectable liver metastases suggested by MDT&#xD;
&#xD;
          3. RAS/BRAF gene wild-type states&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          5. Life expectancy ≥ 3 months&#xD;
&#xD;
          6. Good hematological function: neutrophil ≥ 1.5x109 / L and platelet count ≥ 100x109 /&#xD;
             L; HB ≥ 9g / dl (within one week before randomization)&#xD;
&#xD;
          7. Normal liver and kidney function: serum bilirubin ≤ 1.5x normal upper limit (ULN),&#xD;
             alkaline phosphatase ≤ 5x ULN, serum transaminase (AST or ALT) ≤ 5x ULN (within one&#xD;
             week before randomization);&#xD;
&#xD;
          8. Sign the written informed consent to participate in the experiment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with liver metastases from colorectal cancer who have previously received&#xD;
             targeted therapy, chemotherapy, radiotherapy or interventional therapy&#xD;
&#xD;
          2. Known or suspected extrahepatic metastasis&#xD;
&#xD;
          3. Patients with known hypersensitivity to any component of the study treatment&#xD;
&#xD;
          4. Clinical related coronary heart disease or history of myocardial infarction in the&#xD;
             last 12 months or left ventricular ejection fraction below normal range&#xD;
&#xD;
          5. Acute or subacute intestinal obstruction&#xD;
&#xD;
          6. Pregnancy (no pregnancy confirmed by serum / urine β - hCG) or breastfeeding.&#xD;
&#xD;
          7. Other malignant tumors within 5 years, except for those with skin basal cell carcinoma&#xD;
             or cervical cancer&#xD;
&#xD;
          8. Known drug / alcohol abuse&#xD;
&#xD;
          9. No legal capacity or limited legal capacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianmin Xu, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianmin Xu, MD, Ph.D.</last_name>
    <phone>86-21-64041990</phone>
    <phone_ext>692011</phone_ext>
    <email>xujmin@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wentao Tang, MD, Ph.D.</last_name>
    <phone>86-21-64041990</phone>
    <email>tangwt1988@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianmin Xu, MD,Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Zhen Lou, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhigang Wang, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tao Zhang, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sheng Wang, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kejing Huang, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minhao Yu, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zihua Chen, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yong Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rui Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yifei Pan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chunkang Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yijiu Shi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guiying Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhenning Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lingjun Zhu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 27, 2020</study_first_submitted>
  <study_first_submitted_qc>December 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>September 19, 2021</last_update_submitted>
  <last_update_submitted_qc>September 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xu jianmin</investigator_full_name>
    <investigator_title>Deputy director of the department of general surgery</investigator_title>
  </responsible_party>
  <keyword>Cetuximab</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Triplet Chemotherapeutic Regimen</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Liver Metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

